Abstract
Introduction
The characteristics of oral tongue squamous cell carcinomas (SCC) and the treatment results were reviewed to determine the appropriate treatment strategies.
Materials and Methods
The medical records of 140 patients diagnosed and treated for oral tongue SCC at Yonsei University Health System from January 1995 to December 2004 were reviewed. For statistic analysis, the survival rate was determined using the Kaplan-Meier method with SPSS version 12.0, and the difference in survival rates was evaluated using a log-rank test.
Results
The mean age of the patients with oral tongue SCC patients was 55 (19–85 years old). According to the T, N and pathologic stage, the patients were distributed from a higher to a lower incidence of cases, as follows: T2 (46.4%), T1 (37.9%), T4 (8.5%), and T3 (7.1%); N0 (65%), N1 (20.7%), N2 (13.6%), and N3 (0.7%); and stage Ⅰ (31.4%), stage Ⅱ (25.7%), stage Ⅳ (22.2%), and stage Ⅲ (20.7%). Local and regional recurrence and distant metastasis was present in 13.6%, 5% and 4.2% of patients, respectively. The five-year survival rate was 72.2%, and the prognostic factors for oral tongue SCC included neck metastasis, pathologic stage of the disease, cell differentiation, treatment modality, neck dissection as part of the treatment plan, and neck node recurrence.
References
1. Aksu G, Karadeniz A, Saynak M, Fayda M, Kadehci Z, Kocaelli H. Treatment results and prognostic factors in oral tongue cancer: analysis of 80 patients. Int J Oral Maxillofac Surg. 2006; 35:506–13.
2. Robbins KT, Medina JE, Wolfe GT, Levine PA, Sessions RB, Pruet CW. Standardizing neck dissection terminology- Official report of the academy's committee for head and neck surgery and oncology. Arch Otolaryngol Head Neck Surg. 1991; 117:601–5.
3. Lam L, Logan RM, Luke C, Rees GL. Retrospective study of survival and treatment pattern in a cohort of patients with oral and oropharyngeal tongue cancers from 1987 to 2004. Oral Oncol. 2007; 43:150–8.
4. Gorsky M, Epstein JB, Oakley C, Le ND, Hay J, Stevenson-Moore P. Carcinoma of the tongue: a case series analysis of clinical presentation, risk factors, staging, and outcome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004; 98:546–52.
5. El-Husseiny G, Kandil A, Jamshed A, Khafaga Y, Saleem M, Allam A, et al. Squamous cell carcinoma of the oral tongue: an analysis of prognostic factors. Br J Oral Maxillofac Surg. 2000; 38:193–9.
6. AlRajhi N, Khafaga Y, El-Husseiny J, Saleem M, Mourad W, Al-Otieschan A, et al. Early stage carcinoma of oral tongue: prognostic factors for local control and survival. Oral Oncol. 2000; 36:508–14.
7. Nason RW, Anderson BJ, Gujrathi DS, Abdoh AA, Cooke RC. A retrospective comparison of treatment outcome in the posterior and anterior tongue. Am J Surg. 1996; 172:665–70.
8. Sessions DG, Spector GJ, Lenox J, Haughey B, Chao C, Marks J. Analysis of treatment results for oral tongue cancer. Laryngoscope. 2002; 112:616–25.
9. Amdur RJ, Parsons JT, Mendenhall WM, Million RR, Stringer SP, Cassisi NJ. Postoperative irradiation for squamous cell carcinoma of the head and neck: an analysis of treatment results and complications. Int J Radiat Oncol Biol Phys. 1989; 16:25–36.
10. Woolgar JA, Rogers SN, Lowe D, Brown JS, Vaughan ED. Cervical lymph node metastasis in oral cancer: the importance of even microscopic extracapsular spread. Oral Oncol. 2003; 39:130–7.
11. Yuen AP, Lam KY, Chan AC, Wei WI, Lam LK, Ho WK, et al. Clinicopathological analysis of elective neck dissection for N0 neck of early oral tongue carcinoma. Am J Surg. 1999; 177:90–2.
12. Kim NK. Prognostic significance of perineural and vascular invasion in oral squamous cell carcinoma [dissertation]. Seoul: Graduate School, Yonsei University;2010.
13. Zba ¨ren P, Nuyens M, Caversaccio M, Stauffer E. Elective neck dissection for carcinomas of the oral cavity: occult metastases, neck recurrences, and adjuvant treatment of pathologically positive necks. Am J Surg. 2006; 191:756–60.
14. Franceschi D, Gupta R, Spiro RH, Shah JP. Improved survival in the treatment of squamous carcinoma of the oral tongue. Am J Surg. 1993; 166:360–5.
15. Schiff BA, Roberts DB, El-Naggar A, Garden AS, Myers JN. Selective vs modified radical neck dissection and postoperative radiotherapy vs observation in the treatment of squamous cell carcinoma of the oral tongue. Arch Otolaryngol Head Neck Surg. 2005; 131:874–8.
16. Gonza′lez-Garcl′a R, Naval-Gl′as L, Sastre-Pe′rez J, Rodrl′guez-Campo FJ, Mun ̃oz-Guerra MF, Usandizaga JL, et al. Contralateral lymph neck node metastasis of primary squamous cell carcinoma of the tongue: a retrospective analytic study of 203 patients. Int J Oral Maxillofac Surg. 2007; 36:507–13.
17. Liao CT, Wang HM, Hsieh LL, Chang JT, Ng SH, Hsueh C, et al. Higher distant failure in young age tongue cancer patients. Oral Oncol. 2006; 42:718–25.
18. Byers RM, Weber RS, Andrews T, McGill D, Kare R, Wolf P. Frequency and therapeutic implications of “skip metastases”in the neck from squamous carcinoma of the oral tongue. Head Neck. 1997; 19:14–9.
19. Woolgar JA. Histological distribution of cervical lymph node metastases from intraoral/oropharyngeal squamous cell carcinomas. Br J Oral Maxillofac Surg. 1999; 37:175–80.
20. Traynor SJ, Cohen JI, Gray J, Andersen PE, Everts EC. Selective neck dissection and the management of the nodepositive neck. Am J Surg. 1996; 172:654–7.
21. Kowalski LP, Carvalho AL. Feasibility of supraomohyoid neck dissection in N1 and N2a oral cancer patients. Head Neck. 2002; 24:921–4.
22. Andersen PE, Warren F, Spiro J, Burningham A, Wong R, Wax MK, et al. Results of selective neck dissection in management of the nodepositive neck. Arch Otolaryngol Head Neck Surg. 2002; 128:1180–4.
23. Veness MJ, Morgan GJ, Sathiyaseelan Y, Gebski V. Anterior tongue cancer and the incidence of cervical lymph node metastases with increasing tumour thickness: should elective treatment to the neck be standard practice in all patients? ANZ J Surg. 2005; 75:101–5.
24. O'Brien CJ, Lauer CS, Fredricks S, Clifford AR, McNeil EB, Bagia JS, et al. Tumor thickness influences prognosis of T1 and T2 oral cavity cancer-but what thickness? Head Neck. 2003; 25:937–45.
Table 1.
Cases (n=140) | Percentage of cases (%) | 5-year survival (%) | P value | ||
---|---|---|---|---|---|
Gender | |||||
Male | 94 | 67.1 | 72.6 | >0.05 | |
Female | 46 | 32.9 | 71.5 | ||
Smoking1 (n=125) | |||||
Smoker | 38 | 30.4 | 68.3 | >0.05 | |
Non-smoker | 87 | 69.6 | 74.8 | ||
Pathologic T stage | |||||
T1 | 53 | 37.9 | 77.4 | ||
T2 | 65 | 46.4 | 70.5 | >0.05 | |
T3 | 10 | 7.1 | 68.5 | ||
T4 | 12 | 8.6 | 52.5 | ||
Tumor size | |||||
<2 cm | 53 | 37.9 | 77.4 | >0.05 | |
≥2 cm | 87 | 62.1 | 68.7 | ||
Pathologic N stage | |||||
N0 | 91 | 65 | 78.1 | ||
N1 | 29 | 20.7 | 51.5 | ||
N2a, b | 15 | 10.7 | 67.1 | <0.05 | |
N2c | 4 | 2.9 | 66 | ||
N3 | 1 | 0.7 | NA2 | ||
Neck metastasis | |||||
Negative | 91 | 65 | 78.1 | <0.05 | |
Positive | 49 | 35 | 60.3 | ||
Pathologic Stage | |||||
Ⅰ | 44 | 31.4 | 82.4 | ||
Ⅱ | 36 | 25.7 | 74.1 | <0.05 | |
Ⅲ | 29 | 20.7 | 59.3 | ||
Ⅳ | 31 | 22.2 | 64.7 | ||
Stage (divided as early/ late) | |||||
Early | 79 | 564 | 78.8 | <0.05 | |
Late | 61 | 43.6 | 62.2 | ||
Cell differentiation3 (n=115) | |||||
Well | 49 | 42.6 | 67.9 | ||
Moderate | 55 | 47.8 | 73.6 | <0.05 | |
Poor | 11 | 9.6 | 36.3 | ||
Surgical margin | |||||
Negative | 122 | 87.1 | 76.5 | ||
Positive | 11 | 7.9 | 40 | >0.05 | |
Epithelial dysplasia | 7 | 5 | 57.1 | ||
Perineural invasion, perivascular invasion | |||||
Positive | 4 | 2.8 | NA | ||
Treatment modality | |||||
Surgery only | 77 | 55 | 84.1 | <0.05 | |
Combined therapy | 63 | 45 | 60.2 | ||
Method of neck dissection | |||||
No neck dissection | 31 | 22.1 | 91.2 | ||
Ipsilateral selective4 | 14 | 10 | 70.8 | ||
Ipsilateral radical5 | 48 | 34.3 | 87.5 | <0.05 | |
Bilateral (selective+selective) | 33 | 23.6 | 61.7 | ||
Bilateral (radical+selective) | 14 | 10 | 61.5 | ||
Local recurrence | |||||
No recurrence | 121 | 86.4 | 71.7 | <0.05 | |
Recurrence | 19 | 13.6 | 60 | ||
Neck recurrence | |||||
No recurrence | 133 | 95 | 74.9 | <0.05 | |
Recurrence | 7 | 5 | NA |
Table 3.
no ND (n) | Ipsilateral elective ND | Ipsilateral radical ND | Bilateral elective ND (elective+elective) | Bilateral radical ND (radical+elective) | ||
---|---|---|---|---|---|---|
Neck metastasis | ||||||
Pathologically negative | Percentage (No. of cases/Total cases) 5-year survival | 3.2%* | 3.0% | 0.0% | 9.0% | 0.0% |
(1/31**) | (1/33) | (0/3) | (2/22) | (0/2) | ||
91.2% | 74.3% | NA | 71.4% | NA** | ||
Pathologically | Percentage (No. of cases/Total cases) 5-year survival | NC**** | 0.0% | 9.0% | 18.1% | 0.0% |
Pathologically positive | (0/15) | (1/11) | (2/11) | (0/12) | ||
60.6% | 83.3% | 41.1% | 63.6% | |||
Stage | ||||||
Early stage (Ⅰ, Ⅱ) | Percentage (No. of cases/Total cases) 5-year survival | 3.2% | 0.0% | 0.0% | 13.3% | 0.0% |
(1/31) | (0/30) | (0/2) | (2/15) | (0/1) | ||
91.2% | 84.5% | NC | 61.5% | NA | ||
Late stage (Ⅲ, Ⅳ) | Percentage (No. of cases/Total cases) 5-year survival | 5.5% | 7.1% | 11.1% | 0.0% | |
NC | (1/18) | (1/12) | (2/18) | (0/13) | ||
50.3% | 83.3% | 61.2% | 66.6% |